Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.

Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):791-8.e1. doi: 10.1016/j.cgh.2014.06.031. Epub 2014 Jul 11.

2.

Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers.

McGowan CE, Edwards TP, Luong MU, Hayashi PH.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):799-804. doi: 10.1016/j.cgh.2014.07.056. Epub 2014 Aug 10.

3.

Surveillance for hepatocellular carcinoma: can we focus on the mission?

Kanwal F, El-Serag HB, Ross D.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):805-7. doi: 10.1016/j.cgh.2014.12.016. Epub 2014 Dec 22. No abstract available.

PMID:
25541193
4.

Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers.

Khalili M, Guy J, Yu A, Li A, Diamond-Smith N, Stewart S, Chen M Jr, Nguyen T.

Dig Dis Sci. 2011 May;56(5):1516-23. doi: 10.1007/s10620-010-1439-3. Epub 2010 Nov 3.

5.

Surveillance for hepatocellular carcinoma: how can we do better?

Hassett M, Yopp AC, Singal AG.

Am J Med Sci. 2013 Oct;346(4):308-13. doi: 10.1097/MAJ.0b013e31828318ff.

PMID:
23426089
6.

Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB.

Hepatology. 2010 Jul;52(1):132-41. doi: 10.1002/hep.23615.

7.

Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB.

Ann Intern Med. 2011 Jan 18;154(2):85-93. doi: 10.7326/0003-4819-154-2-201101180-00006.

PMID:
21242365
8.

Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, Singal AG.

Clin Gastroenterol Hepatol. 2014 May;12(5):870-7. doi: 10.1016/j.cgh.2013.09.053. Epub 2013 Oct 2.

9.

Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.

Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA.

Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):793-9. doi: 10.1158/1055-9965.EPI-11-1005. Epub 2012 Feb 28.

10.

Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.

Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH.

Am J Gastroenterol. 2015 Jun;110(6):836-44; quiz 845. doi: 10.1038/ajg.2015.100. Epub 2015 Apr 14.

PMID:
25869392
11.

Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis.

Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Clin Gastroenterol Hepatol. 2014 Nov;12(11):1927-33.e2. doi: 10.1016/j.cgh.2014.02.025. Epub 2014 Feb 26.

PMID:
24582947
12.

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.

Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K.

Health Technol Assess. 2007 Sep;11(34):1-206. Review.

13.

Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey.

Chalasani N, Said A, Ness R, Hoen H, Lumeng L.

Am J Gastroenterol. 1999 Aug;94(8):2224-9.

PMID:
10445554
14.

The Effect of Hepatocellular Carcinoma Surveillance in an Urban Population With Liver Cirrhosis.

Nusbaum JD, Smirniotopoulos J, Wright HC, Dash C, Parpia T, Shechtel J, Chang Y, Loffredo C, Shetty K.

J Clin Gastroenterol. 2015 Nov-Dec;49(10):e91-5. doi: 10.1097/MCG.0000000000000306.

PMID:
25751372
15.

Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time.

Lee E, Edward S, Singal AG, Lavieri MS, Volk M.

Clin Gastroenterol Hepatol. 2013 Apr;11(4):437-40. doi: 10.1016/j.cgh.2012.11.029. Epub 2012 Dec 12.

PMID:
23247324
16.

A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis.

Iavarone M, Lampertico P, Ronchi G, Del Ninno E, Zanella A, Colombo M.

J Viral Hepat. 2003 Nov;10(6):423-6.

PMID:
14633174
17.

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M.

Gut. 2001 Feb;48(2):251-9.

18.

Serum alpha-fetoprotein may have a significant role in the surveillance of hepatocellular carcinoma in hepatitis B endemic areas.

Sinn DH, Yi J, Choi MS, Kim YJ, Gwak GY, Lee JH, Koh KC, Paik SW, Yoo BC.

Hepatogastroenterology. 2015 Mar-Apr;62(138):327-32.

PMID:
25916058
19.

[Screening of hepatocellular carcinoma and surveillance of patients with cirrhosis: a public health issue].

Trinchet JC, Nahon P, Ganne-Carrie N.

Rev Prat. 2013 Feb;63(2):222-5. Review. French.

PMID:
23513790
20.

Failure rates in the hepatocellular carcinoma surveillance process.

Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA.

Cancer Prev Res (Phila). 2012 Sep;5(9):1124-30. doi: 10.1158/1940-6207.CAPR-12-0046. Epub 2012 Jul 30.

Items per page

Supplemental Content

Write to the Help Desk